Our US development and licensing partner, Apricus Biosciences Inc., yesterday announced (link to press release) their phase 2b results of Fispemifene for the treatment of sexual dysfunction in men with secondary hypogonadism.
Although the testosterone levels were significantly elevated, the symptomatic endpoints were not met in this study population. Fispemifene was well tolerated by the patients, so its’ safety profile remains attractive.
Opportunities for Fispemifene in other male urological conditions have already been studied by our company in the past and we will now return our focus into LUTS and chronic prostatitis opportunities. Fispemifene as a SERM (selective estrogen receptor modulator) has a novel mechanism of action and we continue to strongly believe in its potential for multiple indications.
We will continue licensing discussions with partner candidates in the field of male urological conditions.